ADC Licensing Deal Benchmarks

Median Upfront

$393M

Range: $219M - $556M

Total Deal Value

$2.5B

Range: $1.6B - $3.4B

Royalty Rate

13.4% - 21.9%

Tiered up to 25.9%

Dev Milestones

$526M

Range: $351M - $704M

Model Your Deal

Market Analysis

Antibody-drug conjugates remain one of the hottest modalities in oncology licensing. Phase 2 ADC deals command a median total deal value of $2.5B, with upfront payments ranging from $219M to $556M. The premium reflects strong clinical validation from approved ADCs and a deep pipeline of next-generation linker-payload combinations.

Milestone structures in ADC deals are typically front-loaded toward development milestones ($526M median) because of the technical risk around linker stability, payload potency, and therapeutic index optimization. Regulatory milestones add $841M on average, while commercial milestones can reach $736M.

Royalty rates for ADC licensing transactions typically fall between 13.4% and 21.9% at the base tier, escalating to 17.4%-25.9% on blockbuster sales. The 16% upfront / 84% milestone split is standard for Phase 2 ADC assets with competitive differentiation.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for an ADC licensing deal?

Based on our analysis, Phase 2 ADC licensing deals average $393M in upfront payments, with a range of $219M to $556M depending on target validation, payload novelty, and competitive positioning.

How are ADC deal milestones typically structured?

ADC deals allocate approximately 84% of total deal value to milestones. Development milestones ($526M) make up the largest share, followed by commercial milestones ($736M) and regulatory milestones ($841M).

What royalty rates are standard for ADC out-licensing?

Base royalty rates for ADC transactions range from 13.4% to 21.9%, with tiered escalations reaching 17.4%-25.9% on peak sales exceeding $1 billion. Rates are influenced by target novelty, competitive landscape, and territorial scope.

How do ADC deal terms compare to other modalities?

ADC licensing deals typically command a premium over standard monoclonal antibodies due to the added complexity of linker-payload technology and the demonstrated blockbuster potential of approved ADCs. Total deal values tend to be 20-40% higher than naked antibody deals at equivalent clinical stages.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

ADC Licensing Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Bispecific Antibody Deals

Breast Cancer Deal Benchmarks

Phase 2 Deal Benchmarks

Oncology Deal Overview 2026

Ready to Calculate Your Deal Terms?